SEC Filings
Blackstone Funds Can Cover Up To $455 Million Of Boston Scientific's Heart-Pump Development Costs
The payback to Blackstone is capped at 2.5 times what it funds, plus royalties, and nothing has been booked yet.
BSX
Boston Scientific (BSX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
Boston Scientific Stock Plunges 8%, Wiping Out $5.4 Billion After Cyberattack Forces Outlook Cut
The device maker trimmed its 2026 profit outlook after an August cybersecurity incident and guided to lower fourth-quarter sales.
Earnings
Boston Scientific Calls 2027 The Trough As Watchman And Heart-Rhythm Drags Persist
CEO Mike Mahoney says the medical-device maker will be challenged to grow sales and adjusted EPS in 2027, with 2028 the target for a rebound.
Earnings
Boston Scientific CFO: 'We Need To Rebuild Confidence In Our Forecasts'
Management owned up to missed guidance and launch slips of about six months, and pointed to a revamped forecasting process.
Earnings
Boston Scientific Sales Rise Just 1.5% In Third Quarter, And It Guides To A Fourth-Quarter Drop
The medical device maker's per-share profit fell to $0.40 from $0.51, and it forecast fourth-quarter sales down 3.0% to 1.0%.
SEC Filings
Boston Scientific Names Joe Fitzgerald COO And Splits Reporting Into Three Segments In 2027
Fitzgerald, 63, gets a $1,050,000 base salary and a $7,000,000 equity award as COO starting January 1, 2027, the 8-K says.